A novel ribozyme, capable of selectively cleaving the bcr-abl mRNA of a cell containing the Philadelphia Chromosome, thereby blocking synthesis of BCR-ABL protein is provided.

Ribozymes effective to inhibit bcr-abl expression and the use of ribozymes to block proliferation of leukemia carrying the bcr-abl gene are disclosed.

The reagent is used for targeting degradation of Bcr-Abl and c-Abl protein and treating Philadelphia chromosome-positive tumor.

The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject.

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

An ABL processing unit (33) applies a processing, which is emulated from an ABL (Automatic Beam current Limiter) processing, to an image signal.

Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia.

Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

Also provided are methods of decreasing expression of a BCR-ABL gene in a cell or in a subject to treat a BCR-ABL-related disease.

Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

Said inhibitors question are more particularly inhibitors of tyrosine kinases c-abl (bcr/abl), c-kit and /or tyrosine kinase associated with the PDGF receptor.

The invention relates to the use of a c-Abl-.

The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia.